Maria Gemelli

Flying back from the EORTC Spring Meeting 2026 in Gdańsk ✈️ Grateful for these inspiring days, great discussions and new connections in oncology research. #EORTC #Lungcancer

Great discussions at the EORTC Lung Cancer Group meeting in Gdańsk. A real privilege to work with such a collaborative and forward-thinking community—especially encouraging to see new voices actively contributing to study design and research priorities. You are welcome!! #EORTC

🫁 Can we safely stop #Immunotherapy after 2 years in advanced #NSCLC? I-STOP tackles one of the most debated questions in #ThoracicOncology. Discontinuation feasible in selected patients sciencedirect.com/science/articl… #LungCancer #Oncology #OncTwitter #MedTwitter #ICI #immuno

Do we need to change the SoC Ttx for Pancoast NSCLC🫁? Cohort of cases treated: induction CTIO —>Surgery. pCR 100%, strong prognostic marker in these rare 🫁.We discuss challenges to apply this approach in daily practice. High expertise surgery needed authors.elsevier.com/sd/article/S20…

CIOT 2025 just concluded in Venice: top-notch content and inspiring discussions. Thank you all — see you next year in Palermo! #Oncology #LungCancer #CIOT

Dr. @TonyMok9 discusses #EGFR at #CIOT25. Emerging combinations like MARIPOSA and FLAURA2 improving outcomes - key is patient selection. Chemo-IO is out based on CM722 and KN789 but HARMONi could change things if OS superior. ADCs in 3L instead of 2L?

📢 Now Online! Happy to share our latest meta-analysis on the role of ICIs in PD-L1 negative NSCLC. Grateful to all the co-authors 🔗 Full article here: doi.org/10.1016/j.lung… #NSCLC #immunotherapy #lungcancer

Exciting days at the EORTC Lung Cancer Group Spring Meeting! Innovative proposals, great teamwork, and strong support for young researchers. Happy to be part of this! #EORTC #LungCancer

Cooperative Academic groups like #EORTC Lung Cancer Group are amazing!We have made our Spring meeting in Genova 🇮🇹with an outstanding group of Young Investigators 👏🏻.Lots ideas for future academic trials to ⬆️outcome of pts with 🫁 cancers. Working Together makes us stronger💪🏻

Wrapping up my ESMO experience and heading home. It’s been a whirlwind of emotions…..the first time for me as a speaker, exciting new data, and the pleasure of reconnecting with colleagues old and new. Thank you for the incredible moments! #ESMO2024

Just returned from WCLC and wanted to extend a huge thank you to the @IASLC Academy for the incredible experience and opportunity! #WCLC2024 #IASLC

A friendly competition among the 2024 IASLC Academy class will culminate at #WCLC24. Participants Sally Lau, MD, and @MariaGemelli89 share thoughts about the experience in #ILCN: bit.ly/4dqszQO #LCSM

Stop pembro after 2 years? In 43,359 pts that received up-front pembrolizumab for an advanced NSCLC, continuation beyond 2 years was not associated with better OS than a fixed 2-year treatment, HR = 0.97 [0.75–1.26] p = 0.95. @arousseaumd sciencedirect.com/science/articl…

Multidisciplinary consensus statement & practical recommendations on neoadjuvant & adjuvant therapy for early stage resectable NSCLC from @IASLC now @JTOonline led by Drs. @DoctorJSpicer and Tina Cascone. jto.org/article/S1556-…

#ARTICUNO study finally published! @ESMO_Open 📊 largest dataset of #NSCLC with uncommon #EGFR alterations treated with #osimertinib 🧬data on very rare alterations (snv, fusion, KDD), #intracranial activity, and #resistance mechanisms 🔎 #E709 mut->lack of benefit

Engaging discussions this morning on our @IASLC Academy projects! Great to have Academy co-chair @ChristianRolfo join us as our group mentor, providing tailored advice on our initiatives. #lcsm

@DoctorJSpicer @MThoracics Thrilled and proud to be working with you @DoctorJSpicer, @LyndonCWalsh @MThoracics! Excitedly awaiting the results of other super interesting projects on prognostic and predictive factors in resectable NSCLC!!

Should we infuse IO in the morning? Intriguing work just published: Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy. We may need to analyze timing of IO infusion in phase III trials to guide us in our daily clinic. cell.com/cell/fulltext/…

Ph III CM77T trial @NEJM: Periop Nivo in Stage IIA-IIIB NSCLC: - neoadj nivo+chemo x 4 + 1yr adj nivo v neoadj chemo x 4 + 1yr adj pbo - EFS HR 0.58 (p<0.001), pCR 25.3% v 4.7% favoring nivo+chemo - g3+ TRAEs in 32.5% v 25.2% #TCascone @Oncoalert #LCSM nejm.org/doi/full/10.10…

US FDA accepts for priority review BLA of zenocutuzumab (HER2/3 bispecific antibody) for patients with #NRG1 fusion NSCLC or pancreatic cancer. Fusions in NRG1 (neuregulin) are rare but important, can be missed by DNA NGS, best detected with RNA-seq. ir.merus.nl/news-releases/…